In addition, the FLAURA trial showed that the clinical efficacy of osimertinib in the first‐line treatment of advanced NSCLC with EGFR mutations was significantly superior to that of the first‐generation EGFR TKIs.4 Here, EGFR is linked to non-small cell lung carcinoma.